Topical Ganciclovir Versus Systemic Aciclovir in the Treatment of Herpetic Keratitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-01

Study Completion Date

2024-12-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Traditional antiviral treatments, including systemic acyclovir, have shown effectiveness in resolving keratitis but can also lead to complications, including ocular surface toxicity and the development of acyclovir-resistant strains of HSV. Topical ganciclovir 0.15% ophthalmic gel presents a safer alternative for managing herpetic keratitis, offering effective viral suppression with minimal toxicity. This study aims to compare the efficacy and safety of topical ganciclovir versus systemic acyclovir in treating herpetic keratitis, providing valuable insights into optimal management strategies for this condition

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis

NCT02382588

Herpes Zoster Keratitis

TERMINATED PHASE2

Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis

NCT03626376

Herpes Simplex Virus Keratitis

WITHDRAWN PHASE4

The Efficacy of Two Potential Diagnostic Assays for Herpes Simplex Keratitis (HSK)

NCT00357812

Herpes Simplex Keratitis

COMPLETED

Efficacy of Acyclovir in Combination With a Glucocorticosteroid on UV-Induced Herpes Labialis

NCT00736437

Herpes Labialis

COMPLETED PHASE2

Herpetic Eye Disease Study (HEDS) II

NCT00000139

Keratitis, Herpetic Ocular Herpes Simplex Herpes Simplex

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Herpetic Keratitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ganciclovir

Group Type ACTIVE_COMPARATOR

Ganciclovir (GCV)

Intervention Type DRUG

Ganciclovir is an anti-viral drug

Systemic acyclovir

Group Type ACTIVE_COMPARATOR

Acyclovir 400 MG

Intervention Type DRUG

Acyclovir is used to treat infections caused by certain types of viruses.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acyclovir 400 MG

Acyclovir is used to treat infections caused by certain types of viruses.

Intervention Type DRUG

Ganciclovir (GCV)

Ganciclovir is an anti-viral drug

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with herpetic keratitis

Exclusion Criteria

* Patients with known allergies to ganciclovir or acyclovir
* Severe ocular surface disease
* Those who have previously received antiviral therapy for herpetic keratitis within the last month

Eligible Sex

ALL

Accepts Healthy Volunteers

No